Genextest LLC is an official distributor of Myriad in Estonia and Russia.
Myriad offers an array of genetic tests, prognostic tests, and personalized medicine tests to healthcare providers to help them assess a patient’s increased cancer risk, disease aggressiveness, optimize efficacy of chemotherapy and identify patients’ most suitable for therapy.
EndoPredict® is the only test that answers the following three important clinical questions…
- Can chemotherapy be avoided? (individual risk at 10 years)
- What is the absolute benefit from chemotherapy? (individual chemotherapy benefit)
- Can endocrine therapy be stopped after 5 years? (individual risk up to 15 years)
… to optimize treatment for breast cancer patients.
Prolaris® is a molecular diagnostic test that measures the expression level of genes involved with tumor proliferation to predict disease outcome. Prolaris can be used in conjunction with other clinical parameters to determine prostate cancer aggressiveness.
myChoice CDx is the first and only FDA-approved tumor test that determines homologous recombination deficiency status by detecting BRCA1 and BRCA2 (sequencing and large rearrangement) variants and assessing genomic instability using three critical biomarkers: loss of heterozygosity, telomeric allelic imbalance and large-scale state transitions.
myChoice CDx PLUS identifies patients that are most likely to benefit from PARP inhibitors. It is the only commercially available tumor test that has been designed to detect large rearrangements which account for 5% of all ovarian cancer mutations.